Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MedicalCV, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Mechanical heart valve maker plans initial public offering to support marketing of its Omnicarbon 3000 monoleaflet, pyrolytic carbon heart valve following FDA approval July 26 (1"The Gray Sheet" Aug. 6, 2001, p. 12). The offering includes 1.5 mil. units at $4.50 each; the units consist of one share of common stock and a warrant to purchase an additional share at $6.50 per share. Estimated proceeds of $5.6 mil. will primarily be used for sales and marketing initiatives and working capital. MedicalCV also plans to pursue FDA approval of the Omnicarbon 4000 by late 2004, incorporating the firm's UPP Carbon coating technology. Other R&D projects include a bi-leaflet valve. Competing with mechanical valve market leader St. Jude as well as Sulzer Carbomedics, Edwards Life Sciences, Medtronic, Sorin Biomedica, ATS Medical and MCRI in the $580 mil. worldwide heart valve market, MedicalCV's revenues increased 6% to $2.9 mil. for the year ended April 30 and consisted mostly of European sales. The Inver Grove Heights, Minnesota firm had a net loss of $3.2 mil. for the year. Equity Securities Investments is managing underwriter for the offering

You may also be interested in...

MedicalCV's Omnicarbon Heart Valve To Launch In August After 15-Year Wait

MedicalCV aims to capture 1-2% of the roughly $360 mil. worldwide mechanical heart valve market over the next year after gaining FDA approval of its Omnicarbon pyrolite ceramic-based heart valve on July 26.

Warning Letter Roundup & Recap – 26 January 2021

No device-related warning letters were released by the US FDA the week of 26 January.

EU Crunch Time For Two Drugs That Lost Their Fast-Track Status

Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts